10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Gastric Cancer
7 articles
Immunotherapy Breakthrough: PD-1/PD-L1 Inhibitors Show Promise in Advanced Gastroesophageal Cancers
Meta-analysis reveals PD-1/PD-L1 inhibitors improve survival in advanced gastroesophageal cancers.
PD-L1 Expression Predicts Immunotherapy Benefit in Advanced Gastroesophageal Cancer
Meta-analysis shows PD-L1 levels predict immunotherapy efficacy in gastroesophageal adenocarcinoma
Genetic Variants Linked to Higher Mortality Risk in Cancer Chemotherapy
Meta-analysis reveals DPYD gene variants significantly increase death risk in fluoropyrimidine chemotherapy.
Triplet Chemotherapy Shows Promise in Advanced Gastric Cancer: MATCH Trial Results
DOS chemotherapy improves tumor response in locally advanced gastric cancer compared to SOX regimen
Ramucirumab Shows Promise After Immunotherapy in Advanced Gastroesophageal Cancer
Study suggests ramucirumab may benefit certain patients with advanced gastroesophageal cancer after immunotherapy
Sintilimab Boosts Survival in Advanced Gastric Cancer: ORIENT-16 Trial Results
Immunotherapy drug sintilimab improves survival in advanced gastric cancer when added to chemotherapy.
Pembrolizumab Plus Chemo Boosts Survival in Advanced Gastric Cancer
Study shows pembrolizumab with chemotherapy improves outcomes in HER2-negative gastric cancer